98%
921
2 minutes
20
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020-January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138992 | PMC |
http://dx.doi.org/10.3201/eid3006.230975 | DOI Listing |
J Appl Microbiol
September 2025
Laboratory of Food Microbiology and Hygiene, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-4-4 Kagamiyama, Higashihiroshima 739-8528, Japan.
Aims: This study aims to investigate the genomic profile of a multidrug-resistant Escherichia coli strain, 160-11H1, co-carrying an extended-spectrum β-lactamase (ESBL) and the plasmid-mediated mobile colistin resistance gene, mcr-5.
Methods And Results: The entire genome of the strain was sequenced using Illumina MiSeq and Oxford Nanopore platforms, and de novo assembly was performed using Unicycler. The genome size was 5 031,330 bp and comprised 5 140 coding sequences.
Mol Ther Methods Clin Dev
June 2025
Precision Safety, Pharma Product Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
Adeno-associated virus (AAV) vectors are widely used in gene therapy, particularly for liver-targeted treatments. However, predicting human-specific outcomes, such as transduction efficiency and hepatotoxicity, remains challenging. Reliable models are urgently needed to bridge the gap between preclinical studies and clinical applications.
View Article and Find Full Text PDFCan Vet J
September 2025
Department of Large Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Saskatchewan S7N 5B4 (Pollock, Campbell, Waldner); Faculty of Veterinary Medicine, University of Calgary, 11877 85 Street NW, Calgary, Alberta T3R 1J3 (Windey
Objective: Our objective was to estimate the seroprevalences of 6 serovars in beef calves at or near fall weaning and assess how concentrations of serovar antibody titers in weaning-age calves varied with herd vaccination programs.
Animals: Serum was collected from 1922 beef calves from 106 herds in the Canadian Cow-Calf Surveillance Network (C3SN).
Procedure: A microscopic agglutination test was used to measure antibody titers for serovars Bratislava, Canicola, Grippotyphosa, Hardjo, Icterohaemorrhagiae, and Pomona.
Transl Anim Sci
August 2025
Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA.
During disease, there may be increased local demands for zinc (Zn) and vitamin A to support pathogen response. This study evaluates the effects of intranasal Zn and vitamin A treatments on steers experimentally infected with bovine respiratory disease (BRD) pathogens, bovine respiratory syncytial virus (BRSV) and , hypothesizing that steers treated with Zn and vitamin A (VA) will have improved recovery to BRD challenge. Forty-eight Angus crossbred steers (333 ± 4.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Diseases, Beijing, China.
Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world's population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease.
View Article and Find Full Text PDF